Rochester, NY -- (SBWIRE) -- 12/04/2013 -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) “OCLS”, announced today that it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company's new Microcyn(R) Scar Management HydroGel. The prescription product is intended for the management of old and new hypertrophic and keloid scarring resulting from burns, general surgical procedures and trauma wounds. OCLS U.S. dermatology partner, Quinnova Pharmaceuticals, intends to commercialize the product in the first half of 2014.
Investors seem to be excited about this news as OCLS gaped up over 131% in pre-market trading, and is currently up over 200% at the time of this update.
Oculus Innovative (NASDAQ:OCLS) will probably get a lot of attention over the next few days. The more traders paying attention to a stock the better the chance for price swings smart traders can profit from. The more eyeballs the better. This is especially true for OTC stocks where investor awareness generated buzz creates big price moves every day.
To learn how investor awareness campaigns affect stock prices and how to profit from those moves click the link to sign up. IT’S FREE!!
WhisperfromWallStreet has been teaching investors how to trade OTC stocks since 2005. We clearly explain the market dynamics behind most major moves in the OTC markets and provide readers with time tested, easy to follow strategies they can use to stay ahead of the pack.
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)